Share

September 06, 2016; 87 (10) Editorial

Does early (treatment in) BENEFIT lead to late MS benefit?

Brian C. Healy, Brian G. Weinshenker
First published August 10, 2016, DOI: https://doi.org/10.1212/WNL.0000000000003070
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
214

Share

Article Information

vol. 87 no. 10 970-971
DOI: 
https://doi.org/10.1212/WNL.0000000000003070
PubMed: 
27511185
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published August 10, 2016.

Article Versions

Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. Brian C. Healy, PhD and
    2. Brian G. Weinshenker, MD
  1. Brian C. Healy, PhD and
    2. Scientific Advisory Boards:

    1. Member of Biogen Worldwide Medical Biostatistics MS Advisory Board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Statistical Methods in Medical Research, editorial board, 2008-Present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Merck Serono, 12/2009-Present Novartis, 10/2012-9/2015 Genzyme, 8/2014-7/2015 Google Life Sciences, 9/2015-Present

    Research Support, Government Entities:

    1. NIH, 1UH2TR000890-01, Statistician, 2013-Present NIH, 1R01HL113272-02, Statistician, 2013-Present NIH, 1UL1TR001102-07, Statistician, 2013-Present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Brian G. Weinshenker, MD
    3. Scientific Advisory Boards:

    1. (1) Novartis data safety monitoring board member (2) Biogen Idec data safety monitoring board member (3) Mitsubishi Pharmaceuticals data safety monitoring board member

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 1. Canadian Journal of Neurological Sciences, editorial board member, 2006-present; no compensation 2. Turkish Journal of Neurology, editorial board member, 2005-present; no compensation 3. Neurology, editorial board member, 2014-present; no compensation

    Patents:

    1. 1) NMO-IgG for diagnosis of neuromyelitis optica; application 20050112116; patent issued and technology licensed to R.S.R. Ltd. and Oxford University

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Chugai Pharmaceuticals

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1)Medimmune Pharmaceuticals, Adjudication Committee Member

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Guthy Jackson Charitable Foundation, sponsor of research in NMO, 10/2008-09/2011

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NMO-IgG for diagnosis of neuromyelitis optica; patent issued and technology licensed to R.S.R. Ltd. and to Oxford University

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Partners Multiple Sclerosis Center (B.C.H.), Brigham and Women's Hospital, Boston; Biostatistics Center (B.C.H.), Massachusetts General Hospital, Boston; and Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN.
  1. Correspondence to Dr. Healy: bchealy{at}partners.org
View Full Text

Article usage

Article usage: August 2016 to December 2022

AbstractFullPdfSource
Aug 2016509068Highwire
Sep 20168088289Highwire
Oct 201679511Highwire
Nov 20164536Highwire
Dec 20162634Highwire
Jan 20173512Highwire
Feb 20172523Highwire
Mar 20172033Highwire
Apr 20172423Highwire
May 20172401Highwire
Jun 20171300Highwire
Jul 20171200Highwire
Aug 20171611Highwire
Sep 20172701Highwire
Oct 20171500Highwire
Nov 20171510Highwire
Dec 20171621Highwire
Jan 20182502Highwire
Feb 20181311Highwire
Mar 20181101Highwire
Apr 2018800Highwire
May 20181402Highwire
Jun 2018800Highwire
Jul 20181000Highwire
Aug 20181101Highwire
Sep 20182683Highwire
Oct 2018500Highwire
Nov 20181500Highwire
Dec 20181300Highwire
Jan 20191310Highwire
Feb 2019711Highwire
Mar 2019600Highwire
Apr 20192101Highwire
May 20195100Highwire
Jun 20192701Highwire
Jul 2019401Highwire
Aug 2019601Highwire
Sep 2019600Highwire
Oct 2019700Highwire
Nov 20191300Highwire
Dec 2019201Highwire
Jan 2020400Highwire
Feb 2020700Highwire
Mar 2020700Highwire
Apr 2020300Highwire
May 2020400Highwire
Jun 2020431Highwire
Jul 2020300Highwire
Aug 2020510Highwire
Sep 20201000Highwire
Oct 2020600Highwire
Nov 20201510Highwire
Dec 2020600Highwire
Jan 2021200Highwire
Feb 2021900Highwire
Mar 20211100Highwire
Apr 2021900Highwire
May 20211901Highwire
Jun 2021300Highwire
Jul 20211900Highwire
Aug 20211500Highwire
Sep 20211000Highwire
Oct 20211100Highwire
Nov 2021800Highwire
Dec 20212312Highwire
Jan 2022400Highwire
Feb 20221900Highwire
Mar 20221600Highwire
Apr 2022500Highwire
May 20221200Highwire
Jun 2022700Highwire
Jul 20221001Highwire
Aug 2022810Highwire
Sep 2022200Highwire
Oct 2022600Highwire
Nov 20221100Highwire
Dec 20221100Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me